Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 170

Sort by

Sort Order Select

Journal Articles

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M. Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R. Chapman, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2023) 141 (15): 1888–1893.

https://doi.org/10.1182/blood.2022019294

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Jonathan R Day, Melissa C. Larson, Carla Casulo, Yucai Wang, Dai Chihara, Brad S. Kahl, Peter Martin, Izidore S. Lossos, Victor M. Orellana-Noia, Richard Burack, Jonathan W. Friedberg, Thomas M. Habermann, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Brian K. Link

Blood (2022) 140 (Supplement 1): 6642–6644.

https://doi.org/10.1182/blood-2022-157083

Published: 2022

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Blood (2022) 140 (Supplement 1): 3666–3668.

https://doi.org/10.1182/blood-2022-164988

Published: 2022

Journal Articles

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

Blood (2022) 140 (Supplement 1): 3543–3545.

https://doi.org/10.1182/blood-2022-157051

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method

Juan Pablo Alderuccio, Russ A. Kuker, David Lehmkuhl, Deukwoo Kwon, Andrea Cordoba, Weizhao Zhao, Izidore S. Lossos, Craig H. Moskowitz, Fei Yang

Blood (2022) 140 (Supplement 1): 4972–4973.

https://doi.org/10.1182/blood-2022-165676

Published: 2022

Journal Articles

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 1921–1923.

https://doi.org/10.1182/blood-2022-164692

Published: 2022

Journal Articles

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Juan Pablo Alderuccio, Isildinha M Reis, Jean L. Koff, Melissa C. Larson, Dai Chihara, Wei Zhao, Sara Haddadi, Thomas M. Habermann, Peter Martin, Jennifer R Chapman-Fredricks, Christopher Strouse, Brad S. Kahl, Jonathon B. Cohen, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers, Izidore S. Lossos

Blood (2022) 140 (Supplement 1): 9340–9341.

https://doi.org/10.1182/blood-2022-162688

Published: 2022

Journal Articles

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Arushi Khurana, Raphael Mwangi, Loretta J. Nastoupil, Patrick M. Reagan, Umar Farooq, Jason T. Romancik, Timothy J. McDonnell, Shaun M Riska, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Thomas E. Witzig, James R. Cerhan, Christopher R. Flowers, Matthew J. Maurer, Grzegorz S. Nowakowski

Blood (2022) 140 (Supplement 1): 2056–2058.

https://doi.org/10.1182/blood-2022-169433

Published: 2022

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Blood (2022) 140 (Supplement 1): 6378–6380.

https://doi.org/10.1182/blood-2022-165616

Published: 2022

Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot

Blood (2022) 140 (Supplement 1): 12066–12067.

https://doi.org/10.1182/blood-2022-158042

Published: 2022

Journal Articles

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Blood (2022) 140 (Supplement 1): 6650–6652.

https://doi.org/10.1182/blood-2022-162758

Published: 2022

Journal Articles

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Paolo Strati, Beth Christian, Peter Martin, Becky Champion, Morton Coleman, Richy Agajanian, Sonali M. Smith, Parameswaran Venugopal, Izidore S. Lossos, Robert Kridel, Roser Calvo, Kara Higgins, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 3606–3608.

https://doi.org/10.1182/blood-2022-159158

Published: 2022

Journal Articles

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3500–3503.

https://doi.org/10.1182/blood-2022-168002

Published: 2022

Journal Articles

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Adam J. Olszewski, L. Elizabeth Budde, Julio Chavez, Nilanjan Ghosh, Manali Kamdar, Izidore S. Lossos, Catherine Diefenbach, Waleed Sabry, Kathleen Dorritie, Ling-Yuh Huw, Song Pham, Ting Jia, Hao Wu, Iris To, Michael C. Wei, Sarit Assouline

Blood (2022) 140 (Supplement 1): 3757–3759.

https://doi.org/10.1182/blood-2022-159594

Published: 2022

Journal Articles

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

Danny Luan, Christopher R. Flowers, Brian K. Link, Jonathan W. Friedberg, Jonathon B. Cohen, Brad S. Kahl, Izidore S. Lossos, Loretta Nastoupil, Matthew J. Maurer, James R. Cerhan, Peter Martin

Blood (2021) 138 (Supplement 1): 338.

https://doi.org/10.1182/blood-2021-146099

Published: 2021

Journal Articles

Long-Term Outcome of Conjunctival Extranodal Marginal Zone Lymphoma: A Large Single-Institution Analysis

Eduardo Saul, Juan Pablo Alderuccio, Isildinha M. Reis, Wei Zhao, Sunil G. Iyer, Gregor Rodriguez, Amrita Desai, Derek Isrow, Arnold M. Markoe, Izidore S. Lossos

Blood (2021) 138 (Supplement 1): 2435.

https://doi.org/10.1182/blood-2021-151710

Published: 2021

Journal Articles

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz

Blood (2021) 138 (Supplement 1): 52.

https://doi.org/10.1182/blood-2021-150572

Published: 2021

Journal Articles

Localized DLBCL of the Tonsil: A U.S. Population-Based Survival Analysis

Jorge A Florindez, Izidore S. Lossos, Juan Pablo Alderuccio

Blood (2021) 138 (Supplement 1): 2522.

https://doi.org/10.1182/blood-2021-154141

Published: 2021

NARROW

Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma

Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Calculation of Metabolic Tumor Volume in Diffuse Large B-Cell Lymphoma Using a Deep Learning-Aided Automated Method

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group

Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Metabolic Tumor Volume Predicts Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Trial

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53- wild Type Mantle Cell Lymphoma

Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study

Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis

Long-Term Outcome of Conjunctival Extranodal Marginal Zone Lymphoma: A Large Single-Institution Analysis

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Localized DLBCL of the Tonsil: A U.S. Population-Based Survival Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only